| data suggest that overexpression of DNMT1, DNMT3a, and DNMT3b might represent a critical event responsible for the epigenetic inactivation of multiple tumor suppressor genes, leading to the development of aggressive forms of sporadic breast cancer | breast, |
| Dnmt3a is a haplo-insufficient tumor suppressor in chronic lymphocytic leukemia and highlights the importance of deregulated molecular events in disease pathogenesis. | leukemia, |
| Dnmt3a Is a Haploinsufficient Tumor Suppressor in CD8+ Peripheral T Cell Lymphoma | lymphoma, |
| provide evidence that Dnmt3a and Dnmt3b function as tumor suppressor genes in the prevention of lymphoid malignancies in mice. | None |
| Mutations in DNMT3A were reported in patients with acute myeloid leukaemia and subsequently in patients with various other haematological malignancies, pointing to DNMT3A as a critically important new tumour suppressor. [Review Article] | None |
| We identified frequent mutations of epigenetic modifiers, most notably mutations of DNMT3A, in 33% of adult MPAL patients. Mutations of activated signaling pathways, tumor suppressors, and transcription factors were also frequent. | None |
| conditional inactivation of Dnmt3a in mouse hematopoietic cells leads to an accumulation of immature progenitors in the thymus, which are less apoptotic. These data demonstrate that Dnmt3a is required for normal T-cell development, and acts as a T-ALL tumor suppressor | None |
| An unexpected oncogenic role for Dnmt3a in MTCL through methylation-independent repression of Dnmt3b. | None |